Abstract
Mitochondrial dysfunction has been widely implicated in the etiology of Alzheimers disease (AD). Evidence shows a mitochondrial-mediated impairment of autophagy that potentiates amyloid-β (Aβ) deposition. Accordingly, recent data obtained from AD models, in which mitochondrial alterations are a prominent feature, demonstrated abnormalities in microtubule network, involving tubulin and tau post-translational modifications. In this review we will discuss mitochondrial- regulated processes where mitochondrial malfunction is likely to start a sequence of events leading to sirtuin- 2 activation, microtubule network breakdown, and impairment of the autophagic pathway. Because sirtuin-2 activity depends on cellular NAD+ availability, mitochondrial regulation of NAD+ levels may contribute to an increase in sirtuinmediated tubulin deacetylation. A vicious cycle become installed which potentiates tau hyperphosphorylation, together with Aβ overproduction and deposition. Overall, targeting microtubule network constitutes a promising strategy for pharmacological therapy in AD.
Keywords: Alzheimer's disease, amyloid-β, autophagy, microtubule network, mitochondria, tau, calcium homeostasis, oxidative phosphorylation, AD development, oxidative stress markers, neurodegeneration, mitochondrial integrity, resonance spectroscopy
Current Alzheimer Research
Title: Mitochondria: The Common Upstream Driver of Amyloid-β and Tau Pathology in Alzheimers Disease
Volume: 8 Issue: 5
Author(s): D. F.F. Silva, A. R. Esteves, C. R. Oliveira and S. M. Cardoso
Affiliation:
Keywords: Alzheimer's disease, amyloid-β, autophagy, microtubule network, mitochondria, tau, calcium homeostasis, oxidative phosphorylation, AD development, oxidative stress markers, neurodegeneration, mitochondrial integrity, resonance spectroscopy
Abstract: Mitochondrial dysfunction has been widely implicated in the etiology of Alzheimers disease (AD). Evidence shows a mitochondrial-mediated impairment of autophagy that potentiates amyloid-β (Aβ) deposition. Accordingly, recent data obtained from AD models, in which mitochondrial alterations are a prominent feature, demonstrated abnormalities in microtubule network, involving tubulin and tau post-translational modifications. In this review we will discuss mitochondrial- regulated processes where mitochondrial malfunction is likely to start a sequence of events leading to sirtuin- 2 activation, microtubule network breakdown, and impairment of the autophagic pathway. Because sirtuin-2 activity depends on cellular NAD+ availability, mitochondrial regulation of NAD+ levels may contribute to an increase in sirtuinmediated tubulin deacetylation. A vicious cycle become installed which potentiates tau hyperphosphorylation, together with Aβ overproduction and deposition. Overall, targeting microtubule network constitutes a promising strategy for pharmacological therapy in AD.
Export Options
About this article
Cite this article as:
F.F. Silva D., R. Esteves A., R. Oliveira C. and M. Cardoso S., Mitochondria: The Common Upstream Driver of Amyloid-β and Tau Pathology in Alzheimers Disease, Current Alzheimer Research 2011; 8 (5) . https://dx.doi.org/10.2174/156720511796391872
DOI https://dx.doi.org/10.2174/156720511796391872 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Oncolytic Coxsackievirus and the Mechanisms of its Effects on Cancer: A Narrative Review
Current Cancer Therapy Reviews Update on Clinical, Pathophysiological and Therapeutic Aspects in ANCAAssociated Vasculitides
Current Drug Discovery Technologies Hallucinations and Delusions in Children and Adolescents
Current Psychiatry Reviews Aligning Animal Models of Clinical Germinal Matrix Hemorrhage, From Basic Correlation to Therapeutic Approach
Current Drug Targets Synergistic Effect of Combined HIV/HCV Immunogens: A Combined HIV-1/HCV Candidate Vaccine Induces a Higher Level of CD8+ T Cell-Immune Responses in HLA-A2.1 Mice
Current HIV Research Tuberculosis and HIV Coinfection–the Challenge in the Prevention, Detection and Treatment of Tuberculosis
Current Bioinformatics Amyloid Beta Protein as a Marker or Risk Factor of Alzheimers Disease
Current Alzheimer Research Central Nervous System Acting Drugs in Treatment of Migraine Headache
Central Nervous System Agents in Medicinal Chemistry Ion Channels and Epilepsy
Current Pharmaceutical Design Use of Intravenous Immunoglobulin in the Treatment of Immune-Mediated Demyelinating Diseases of the Nervous System
Current Pharmaceutical Design FDG-PET Scan in Sarcoidosis: Clinical and Imaging Indications
Current Medical Imaging Withdrawal Notice: Evaluation of Clinical Profile, Diagnostic Tests, And Prognosis of Crypto-coccal Meningitis in HIV Infected Patients in Western India
Infectious Disorders - Drug Targets Synthesis and Biological Activities of New Halophenols
Medicinal Chemistry Kingella kingae: A Pediatric Pathogen of Increasing Importance
Current Pediatric Reviews Pulmonary Cryptococcocal Infection
Current Respiratory Medicine Reviews Impact of HIV on Regional & Cellular Organisation of the Brain
Current HIV Research Super aggregated form of Amphotericin B: a novel way to increase its therapeutic index
Current Pharmaceutical Design The Pathology Induced by Highly Active Antiretroviral Therapy Against Human Immunodeficiency Virus: an Update
Current Medicinal Chemistry Imaging the Earliest Stages of Alzheimers Disease
Current Alzheimer Research Mortality and Morbidity of HIV Infected Patients Receiving HAART: A Cohort Study
Current HIV Research